Evidence map›Paper›PMID 36723856›Full record

ReviewCurrent oncology reports2023

Multimodality Therapies for Localized Prostate Cancer.

Luca F Valle, Tommy Jiang, Adam B Weiner, Robert E Reiter, Matthew B Rettig, John Shen, Albert J Chang, Nicholas G Nickols, Michael L Steinberg, Amar U Kishan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Luca F ValleDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, Suite B265, Los Angeles, CA, 90095, USA.ORCID 0000-0002-5781-4174
Tommy JiangDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Adam B WeinerDepartment of Urology, University of California Los Angeles, Los Angeles, USA.
Robert E ReiterDepartment of Urology, University of California Los Angeles, Los Angeles, USA.
Matthew B RettigDepartment of Hematology/Oncology, University of California Los Angeles, Los Angeles, USA.
John ShenDepartment of Hematology/Oncology, University of California Los Angeles, Los Angeles, USA.
Albert J ChangDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, Suite B265, Los Angeles, CA, 90095, USA.
Nicholas G NickolsDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, Suite B265, Los Angeles, CA, 90095, USA.
Michael L SteinbergDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, Suite B265, Los Angeles, CA, 90095, USA.
Amar U KishanDepartment of Radiation Oncology, University of California Los Angeles, 200 Medical Plaza, Suite B265, Los Angeles, CA, 90095, USA. aukishan@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
NCI NIH HHS P50 CA092131NCI NIH HHS T32 CA009213
6 · The paper itself

Abstract

purpose of reviewMultimodality therapy including radical prostatectomy, radiation therapy, and hormone therapy are frequently deployed in the management of localized prostate cancer. We sought to perform a critical appraisal of the most contemporary literature focusing on the multimodality management of localized prostate cancer. RECENT

findingsMen who are ideal candidates for multimodality therapy include those with unfavorable intermediate-risk disease, high-risk disease, and very high-risk disease. Enhancements in both systemic agents (including second-generation antiandrogens) as well as localized therapies (such as stereotactic body radiotherapy and brachytherapy) are refining the optimal balance between the use of systemic and local therapies for localized prostate cancer. Genomic predictors are emerging as critical tools for more precisely allocating treatment intensification with multimodality therapies as well as treatment de-intensification. Close collaboration among medical oncologists, surgeons, and radiation oncologists will be critical for coordinating evidence-based multimodality therapies when clearly indicated and for supporting shared decision-making in areas where the evidence is mixed.

Indexed as

BrachytherapyProstatic NeoplasmsAndrogen AntagonistsCombined Modality TherapyHumansMaleProstatectomyAndrogen AntagonistsADTGenomicsHormone therapyLocalized prostate cancerRadiationRadical prostatectomyRadiotherapySBRTSurgery

Identifiers

PMID36723856
PMCPMC11288626
OpenAlexW4318753635

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.